David CPA - Savara Chief CFO

SVRA Stock  USD 3.47  0.01  0.29%   

CFO

David CPA is Chief CFO of Savara Inc
Age 56
Address 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047
Phone512 614 1848
Webhttps://www.savarapharma.com

Savara Management Efficiency

The company has return on total asset (ROA) of (0.2639) % which means that it has lost $0.2639 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4796) %, meaning that it created substantial loss on money invested by shareholders. Savara's management efficiency ratios could be used to measure how well Savara manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.34. The current year's Return On Capital Employed is expected to grow to -0.34. At present, Savara's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 458 K, whereas Non Current Assets Total are forecasted to decline to about 11.2 M.
Savara Inc currently holds 26.49 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Savara Inc has a current ratio of 38.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Savara's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 4 records

CFO Age

Marc BelskyKezar Life Sciences
69
Jotin MDIkena Oncology
45
Thomas BurnsXOMA Corp
50
MD CFAProtagenic Therapeutics
53
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. Savara Inc (SVRA) is traded on NASDAQ Exchange in USA. It is located in 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047 and employs 37 people. Savara is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Savara Inc Leadership Team

Elected by the shareholders, the Savara's board of directors comprises two types of representatives: Savara inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Savara. The board's role is to monitor Savara's management team and ensure that shareholders' interests are well served. Savara's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Savara's outside directors are responsible for providing unbiased perspectives on the board's policies.
Anne Erickson, IR Contact Officer
Matthew Pauls, Independent Director
MBA JD, Chairman CEO
Peter Clarke, Executive Operations
David CPA, Chief CFO
Brian Maurer, Head Operations
Charles LaPree, Senior Assurance
Yasmine MD, Senior Development
Kate JD, Senior Counsel
Robert MBA, Chief Officer
Brian MD, Senior Affairs
Kate McCabe, Senior Counsel
MD FACP, Chief Officer
Scott Wilhoit, Executive Commercial

Savara Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Savara a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Savara Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Savara's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Savara Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Savara Inc Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Savara Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Savara. If investors know Savara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Savara listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.43)
Return On Assets
(0.26)
Return On Equity
(0.48)
The market value of Savara Inc is measured differently than its book value, which is the value of Savara that is recorded on the company's balance sheet. Investors also form their own opinion of Savara's value that differs from its market value or its book value, called intrinsic value, which is Savara's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Savara's market value can be influenced by many factors that don't directly affect Savara's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Savara's value and its price as these two are different measures arrived at by different means. Investors typically determine if Savara is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Savara's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.